(NASDAQ: BCTX) Briacell Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.
Briacell Therapeutics's earnings in 2025 is -$11,778,491.On average, 1 Wall Street analyst forecast BCTX's earnings for 2025 to be -$9,755,827, with the lowest BCTX earnings forecast at -$9,755,827, and the highest BCTX earnings forecast at -$9,755,827. On average, 1 Wall Street analyst forecast BCTX's earnings for 2026 to be -$6,565,709, with the lowest BCTX earnings forecast at -$6,565,709, and the highest BCTX earnings forecast at -$6,565,709.
In 2027, BCTX is forecast to generate -$5,341,594 in earnings, with the lowest earnings forecast at -$5,341,594 and the highest earnings forecast at -$5,341,594.